Plant Name: Soymida febrifuga
Taxonomic Information:
Plant ID: NPO20812
Plant Latin Name: Soymida febrifuga
Taxonomy Genus: Soymida
Taxonomy Family: Meliaceae
Plant External Links:
NCBI TaxonomyDB:
1672007
Plant-of-the-World-Online:
941499-1
Used in Medicines:
Country/Region:
IndiaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Ayurveda; SiddhaGeographical Distribution:
India; Bangladesh
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CHRNA7; | |
| BCR; | |
| CA1; CA5B; CA5A; CA6; CA12; | |
| PTGS1; PTGS2; | |
| GFER; NQO2; | |
| RAB9A; NPC1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Nicotinic acetylcholine receptor | CHRNA7 | Neuronal acetylcholine receptor protein alpha-7 subunit | P36544 | CHEMBL2492 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Protein Kinase | BCR | Bcr/Abl fusion protein | P11274 | CHEMBL2096618 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.142E-12 | 2.488E-08 | CA1, CA12, CA5A, CA5B, CA6 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.274E-11 | 1.034E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.424E-11 | 1.034E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.417E-10 | 3.429E-07 | CA1, CA12, CA5A, CA5B, CA6 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.065E-10 | 8.046E-07 | CA1, CA12, CA5A, CA5B, CA6 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.570E-10 | 8.293E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.120E-08 | 7.073E-05 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.876E-07 | 2.320E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 7.398E-07 | 5.197E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, PTGS1, PTGS2, RAB9A |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 8.202E-07 | 5.581E-04 | PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.942E-07 | 5.901E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.189E-06 | 7.617E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.743E-06 | 1.054E-03 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.459E-06 | 1.447E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.916E-06 | 2.379E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.916E-06 | 2.379E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 8.188E-06 | 3.639E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.228E-05 | 5.140E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.228E-05 | 5.140E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.718E-05 | 6.926E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.289E-05 | 8.744E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.976E-12 | 6.522E-11 | CA12, CA1, CA5B, CA5A, CA6 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.037E-11 | 1.161E-09 | CHRNA7, CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.431E-09 | 1.574E-08 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.030E-07 | 8.501E-07 | CYP1A1, CYP1B1, PTGS2, CYP19A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.808E-07 | 3.173E-06 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 5.923E-06 | 3.258E-05 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.582E-05 | 1.217E-04 | CYP1A2, CYP1A1, CYP3A4 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.430E-04 | 1.991E-03 | CYP1A2, CYP1A1, PTGS2, CYP3A4, CYP19A1, PTGS1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.145E-03 | 3.778E-03 | PTGS2, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.401E-03 | 4.203E-03 | PTGS2, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.062E-04 | 1.263E-03 | CYP1A2, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.732E-03 | 4.762E-03 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; PTGS2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Miosis during ocular surgery | NA | PTGS1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
